Spinraza (Nusinersen) Denied by Insurance: Appeal

Spinraza (nusinersen) is an antisense oligonucleotide (ASO) therapy developed by Biogen, FDA-approved for spinal muscular atrophy (SMA) in pediatric and adult patients. SMA is a rare, severe genetic disease caused by loss-of-function mutations in the SMN1 gene, resulting in progressive motor neuron degeneration, muscle weakness, and — in the most severe forms — respiratory failure and death in infancy. Spinraza works by modifying the splicing of the SMN2 backup gene to produce more functional SMN protein. At a list price of approximately $750,000 for the first year (loading doses) and $375,000 annually thereafter, Spinraza is one of the most expensive ongoing therapies in the world. Its cost is the central driver of the complex insurance barriers patients and families face.

What Spinraza Treats

Spinraza is indicated for all types of SMA: Type 1 (the most severe, typically diagnosed in infancy with rapid decline), Type 2 (intermediate, with onset before 18 months), Type 3 (milder, with later onset and preserved ambulation initially), and Type 4 (adult onset). It is administered by intrathecal injection (directly into the spinal canal) and requires lumbar puncture procedures at a medical facility — adding site-of-service requirements to the access challenges.

Why Insurance Denies Spinraza

SMA type and disease stage restrictions are a common basis for denial. Some insurers have attempted to limit coverage of Spinraza to specific SMA types or to patients in earlier disease stages, arguing that patients with more advanced motor neuron loss are less likely to benefit. This position conflicts with FDA labeling (which does not restrict by SMA type or disease stage) and with clinical evidence showing benefit even in patients with longer disease duration.

Genetic confirmation requirements are legitimate but can create barriers if testing is not complete. Spinraza's indication is based on SMA diagnosis, which is confirmed by genetic testing showing biallelic deletion or mutation of SMN1. Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization requires documentation of the SMA genetic diagnosis — without this, no PA will be approved. If genetic testing has not yet been ordered or results are pending, this must be addressed urgently.

Prior authorization is extensive and expensive to manage. Because of the extreme cost, PA processes for Spinraza involve multiple levels of clinical review and may require: SMA diagnosis confirmation, SMN1 genetic test results, baseline motor function assessment (CHOP INTEND, HFMSE, or other validated scales), description of treatment plan, and site of service approval for the intrathecal injection procedures.

Competing therapies — particularly Zolgensma (gene therapy for patients under 2) and Evrysdi (risdiplam, oral SMA medication) — have led some insurers to consider coverage frameworks that favor one agent over another. For older SMA patients or those ineligible for gene therapy, Spinraza may be denied in favor of Evrysdi (oral, less expensive), even when the prescribing physician believes Spinraza is more appropriate.

Site of service restrictions arise because Spinraza injections require lumbar puncture in a clinical setting. Some plans restrict coverage to specific approved facilities, which can limit access for patients in rural areas.

How to Appeal a Spinraza Denial

Confirm and submit complete genetic documentation. Your appeal must include the genetic test report showing SMN1 deletion or mutation. If testing was done at a specialized neuromuscular genetics lab, include the full report, not just a summary. SMA Foundation-certified centers typically have the documentation ready.

Provide functional motor assessments. Include baseline CHOP INTEND scores for infants and young children, HFMSE or RULM scores for older patients, or 6-Minute Walk Test results if applicable. These scores document current motor function and establish a baseline for measuring future response. They also counter any argument that the patient is "too advanced" by demonstrating preserved function worth protecting.

Challenge age and disease stage restrictions. If your insurer denied coverage based on disease stage or SMA type, have your neurologist write a letter explicitly citing the FDA label, which does not limit Spinraza by type or stage. Include published literature showing Spinraza benefit in your specific patient population, and cite CureSMA and Child Neurology Society treatment guidelines.

Address the Evrysdi alternative. If the insurer prefers Evrysdi, your neurologist should explain any clinical reasons why Spinraza is more appropriate — for example, if the intrathecal route is preferred for CNS delivery, if the patient has difficulty swallowing oral medications, or if the physician's clinical judgment and patient/family preference support Spinraza.

Request emergency or expedited review for rapidly progressing infants. SMA Type 1 progresses rapidly, and treatment delay is associated with irreversible motor neuron loss. For infants or rapidly declining patients, requests for emergency coverage decisions are clinically justified and legally supported by urgent care provisions.

Patient Assistance Programs

Biogen offers Biogen Spinraza Patient Support, which includes copay assistance for commercially insured patients and access programs for qualifying uninsured or underinsured patients. Contact Biogen Patient Support at 1-800-456-2255. The SMA Foundation and CureSMA (curesma.org) also provide insurance navigation support and financial assistance resources.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?